Exenatide Acetate
First-in-class GLP-1 receptor agonist derived from Gila monster venom (Exendin-4). Pioneering peptide for diabetes therapy with potent glucose-dependent insulin secretion and gastric emptying delay.
Exenatide Acetate is a classic GLP‑1 receptor agonist that provides glucose‑dependent glycemic control, delays gastric emptying, suppresses appetite and preserves islet function. It is widely used in research and formulation development for type 2 diabetes mellitus and weight management, serving as a well‑established and stable peptide API in the global anti‑diabetic and weight‑loss field.
| Parameter | Specification |
| CAS | 141732-76-5 |
| Molecular Formula | C₁₈₆H₂₈₆N₅₀O₆₂S |
| Molecular Weight | 4246.62 g/mol |
| Category | GLP-1/Metabolic |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Type 2 diabetes, obesity research, GLP-1 mechanism studies |
| CAS | 141732-76-5 |
|---|---|
| Applications |
Related products
-
Lixisenatide
CAS: 320367-13-3Applications: postprandial glucose control, Short-acting GLP-1, Type 2 diabetes -
Mazdutide
CAS: 2259884-03-0Applications: metabolic syndrome, Overweight treatment, Type 2 diabetes -
Dulaglutide
CAS: 923950-08-7 -
Semaglutide
CAS: 910463-68-2Applications: cardiovascular risk reduction, obesity management, Type 2 diabetes